Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.